The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
It is a novel oral NLRP3 inflammasome inhibitor
The NFI is published to promote the rational use of medicines in the country.
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache
ranules now has a total of 38 ANDA approvals from US FDA.
Subscribe To Our Newsletter & Stay Updated
